Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
A Phase II Study of Bipolar Androgen-based Therapy for Men with Androgen Ablation Na�ve Recurrent Prostate Cancer
Protocol Number:
J1298
Phase:
Phase II
Physician:
Samuel Denmeade
Purpose:
To determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the effect of alternating therapy on quality of life and metabolic changes associated with androgen-deprivation therapy
Eligibility:
Must be at least 18 years, Must have good physical status, must have confirmed adenocarcinoma of the prostate, must have had no prior androgen deprivation (AD)therapy as treatment for recurrent or metastatic disease (may have received neoadjuvant, concurrent and/or adjuvant AD therapy in the context of definitive local therapy if it was administered � 1 year prior to recurrence), no prior treatment with second line hormonal therapies, no prior treatment with chemotherapeutic regimens, rising PSA on two successive dates greater than 2 weeks apart, must have � 5 total sites of bone metastases and no evidence for lung, liver or other non-bone parenchymal metastases documented within 28 days of enrollment on trial, may have lymph node metastases with no single lymph node greater than 5 cm short axis diameter, must be asymptomatic with no sites of pain due to prostate cancer, must not require urinary catheterization for voiding, must have normal kidney and liver functions, must have normal heart function, must not be surgically castrated prior to consent
Treatment:
After signing informed consent patients will undergo screening including blood work/ EKGs/ Scans/ among other testing, if patient meets eligibility requirements he will begin androgen deprivation therapy (ADT) with an LHRH agonist (i.e. Zoladex, Lupron or Eligard) if not surgically castrated for a total of 6 months, after this initial 6 months lead-in phase patients will continue on ADT every three months but will also receive an intramuscular gluteal injection with testosterone cypionate (T) every 4 weeks for a total of 3 injections (i.e. 12 week constituting one T cycle), patients will then cycle back to ADT only for 12 weeks (i.e. one ADT cycle), this will then be followed by another 12 week cycle of T injections followed by a 12 week cycle of ADT monotherapy, subjects will then be off study, with the option to continue on intermittent or continuous ADT at the discretion of their treating physician.
Population:
Adult
Last Update
04/16/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer